259 related articles for article (PubMed ID: 23242710)
1. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
[TBL] [Abstract][Full Text] [Related]
2. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
3. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
[TBL] [Abstract][Full Text] [Related]
4. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
5. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
6. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
[TBL] [Abstract][Full Text] [Related]
7. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Nguyen HP; Hübener J; Weber JJ; Grueninger S; Riess O; Weiss A
PLoS One; 2013; 8(4):e62043. PubMed ID: 23626768
[TBL] [Abstract][Full Text] [Related]
8. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
9. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
10. Compromised mitochondrial complex II in models of Machado-Joseph disease.
Laço MN; Oliveira CR; Paulson HL; Rego AC
Biochim Biophys Acta; 2012 Feb; 1822(2):139-49. PubMed ID: 22037589
[TBL] [Abstract][Full Text] [Related]
11. Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models.
Mendonça LS; Nóbrega C; Tavino S; Brinkhaus M; Matos C; Tomé S; Moreira R; Henriques D; Kaspar BK; Pereira de Almeida L
Hum Mol Genet; 2019 Nov; 28(22):3691-3703. PubMed ID: 31127937
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
[TBL] [Abstract][Full Text] [Related]
13. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation.
Chou AH; Yeh TH; Ouyang P; Chen YL; Chen SY; Wang HL
Neurobiol Dis; 2008 Jul; 31(1):89-101. PubMed ID: 18502140
[TBL] [Abstract][Full Text] [Related]
15. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
[TBL] [Abstract][Full Text] [Related]
16. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
[TBL] [Abstract][Full Text] [Related]
17. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Griffin JL; Cemal CK; Pook MA
Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
[TBL] [Abstract][Full Text] [Related]
18. Mutant ataxin-3 with an abnormally expanded polyglutamine chain disrupts dendritic development and metabotropic glutamate receptor signaling in mouse cerebellar Purkinje cells.
Konno A; Shuvaev AN; Miyake N; Miyake K; Iizuka A; Matsuura S; Huda F; Nakamura K; Yanagi S; Shimada T; Hirai H
Cerebellum; 2014 Feb; 13(1):29-41. PubMed ID: 23955261
[TBL] [Abstract][Full Text] [Related]
19. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.
Menzies FM; Huebener J; Renna M; Bonin M; Riess O; Rubinsztein DC
Brain; 2010 Jan; 133(Pt 1):93-104. PubMed ID: 20007218
[TBL] [Abstract][Full Text] [Related]
20. N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation.
Hübener J; Vauti F; Funke C; Wolburg H; Ye Y; Schmidt T; Wolburg-Buchholz K; Schmitt I; Gardyan A; Driessen S; Arnold HH; Nguyen HP; Riess O
Brain; 2011 Jul; 134(Pt 7):1925-42. PubMed ID: 21653538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
